Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo

European Neuropsychopharmacology

Volumn 22, Issue 4, 2012, Pages 308-317

  Robson, Matthew J ^a   Elliott, Meenal ^a   Seminerio, Michael J ^a   Matsumoto, Rae R ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Antidepressant; Depression; Ketamine; Neurite outgrowth; NMDA receptor; Sigma receptor

Indexed keywords

IMIPRAMINE; KETAMINE; SIGMA OPIATE RECEPTOR; SIGMA OPIATE1 RECEPTOR; SIGMA OPIATE2 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SCREENING; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE FIBER GROWTH; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ANIMALS; ANISOLES; ANTIDEPRESSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ETHYLENEDIAMINES; KETAMINE; MALE; MICE; MOTOR ACTIVITY; NERVE GROWTH FACTOR; NEURITES; PC12 CELLS; PROPYLAMINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, SIGMA;

EID: 84857239161     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.08.002     Document Type: Article

References (69)

1. aan het Rot M., Collins K.A., Murrough J.W., Perez A.M., Reich D.L., Charney D.S., Mathew S.J. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol. Psychiatry 2010, 67:139-145.
2. Bechtholt-Gompf A.J., Smith, K.L., John, C.S., Kang, H.H., Carlezon Jr., W.A., Cohen, B.M., Ongür, D., 2011. CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy. Psychopharmacology. 215 (4), 689-695.
3. Bermack J.E., Debonnel G. Modulation of serotonergic neurotransmission by short- and long-term treatments with sigma ligands. Br. J. Pharmacol. 2001, 134:691-699.
4. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000, 47:351-354.
5. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 2006, 7:137-151.
6. Castren E., Rantamaki T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev. Neurobiol. 2010, 70:289-297.
7. Chen X.S., Shu S., Bayliss D.A. HCN1 chnnel subunits are a molecular substrate for hypnotic actions of ketmine. J. Neurosci. 2009, 29:600-609.
8. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22:3099-3108.
9. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., Kammerer W.A., Quezado Z., Luckenbaugh D.A., Salvadore G., Machado-Vieira R., Manji H.K., Zarate C.A. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 2010, 67:793-802.
10. Diazgranados N., Ibrahim L.A., Brutsche N.E., Ameli R., Henter I.D., Luckenbaugh D.A., Machado-Vieira R., Zarate C.A. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-d-aspartate antagonist in patients with treatment-resistant major depressive disorder. J. Clin. Psychiatry 2010, 71(12):1605-1611.
11. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 1997, 54:597-606.
12. Duman R.S., Malberg J., Thome J. Neural plasticity to stress and antidepressant treatment. Biol. Psychiatry 1999, 46:1181-1191.
13. Duman R.S., Nakagawa S., Malberg J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 2001, 25:836-844.
14. Engin E., Treit D., Dickson C.T. Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience 2009, 161:359-369.
15. Fishback J.A., Robson M.J., Xu Y.-T., Matsumoto R.R. Sigma receptors: potential targets for a new class of antidepressant drug. Pharmacol. Ther. 2010, 127:271-282.
16. Frazer A., Benmansour S. Delayed pharmacological effects of antidepressants. Mol. Psychiatry 2002, 7(Suppl. 1):S23-S28.
17. Hashimoto K., Fujita Y., Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology 2007, 32:514-521.
18. Hayashi T., Su T.P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007, 131:596-610.
19. Hayashi T., Su T.P. An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma 1 receptor ligand. Expert Opin. Ther. Targets 2008, 12:45-58.
20. Hayashi T., Maurice T., Su T.P. Ca(2+) signaling via sigma(1)-receptors: novel regulatory mechanism affecting intracellular Ca(2+) concentration. J. Pharmacol. Exp. Ther. 2000, 293:788-798.
21. Hellewell S.B., Bruce A., Feinstein G., Orringer J., Williams W., Bowen W.D. at liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol. 1994, 268:9-18.
22. Hirota K., Sikand K.S., Lambert D.G. Interaction of ketamine with mu2 opioid receptors in SH-SY5Y human neuroblastoma cells. J. Anesth. 1999, 13:107-109.
23. Hustveit O., Maurset A., Oye I. Interaction of chiral forms of ketamine with opiod, phencyclidine, sigma and muscarinic receptors. Pharmacol. Toxicol. 1995, 77:355-359.
24. Ishima T., Nishimura T., Iyo M., Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1656-1659.
25. Kishimoto A., Todani A., Miura J., Kitagaki T., Hashimoto K. The opposite effects of fluvoxmine and sertraline in the treatment of psychotic major depression: a case report. Ann. Gen. Psychiatry 2010, 9:23.
26. Koike H., Iijima M., Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav. Brain Res. 2011, 224:107-111.
27. Kollmar R., Markovic K., Thurauf N., Schmitt H., Kornhuber J. Ketamine followed by memantine for the treatment of major depression. Aust. N. Z. J. Psychiatry 2008, 42:170.
28. 11C]-SA5845 is suitable for imaging of drug competition at sigma receptors-the cases of ketamine and haloperidol. Neurochem. Int. 2008, 53:45-50.
29. Krystal J.H. Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Med. Wkly. 2007, 137:215-216.
30. Kulkarni S.K., Dhir A. Sigma-1 receptors in major depression and anxiety. Expert. Rev. Neurother. 2009, 9:1021-1034.
31. Kulkarni S.K., Dhir A. Current investigational drugs for major depression. Expert. Opin. Investig. Drugs 2009, 18(6):767-788.
32. Larkin G.L., Smith R.P., Beautrais A.L. Trends in US emergency department visits for suicide attempts, 1992-2001. Crisis 2008, 29:73-80.
33. Lauterbach, E., 2011. Dextromethorphan as a potential rapid-acting antidepressant. Med. Hypotheses 76 (5), 717-719.
34. Li L., Xu B., Zhu Y., Chen L., Sokabe M. DHEA prevents Abeta(25-35)-impaired survival of newborn neurons in the dentate gyrus through a modulation of PI3K-Akt-mTOR signaling. Neuropharmacology 2010, 59:323-333.
35. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., Li X.Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
36. Li N., Liu R.J., Dwyer J.M., Banasr M., Lee B., Son H., Li X.Y., Aghajanian G., Duman R.S. Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 2011, 69:754-761.
37. Machado-Vieira R., Salvadore G., Diazgranados N., Zarate C.A. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol. Ther. 2009, 123:143-150.
38. Maeng S., Zarate C.A. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr. Psychiatry Rep. 2007, 9:467-474.
39. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., Manji H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 2008, 63:349-352.
40. Martin A.L., Brown R.E. The lonely mouse: verification of a separation-induced model of depression in female mice. Behav. Brain Res. 2010, 207:196-207.
41. Matsuno K., Kobayashi T., Tanaka M.K., Mita S. Sigma 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur. J. Pharmacol. 1996, 312:267-271.
42. McCracken K.A., Bowen W.D., de Costa B.R., Matsumoto R.R. Two novel sigma receptor ligands, BD1047 and LR172, attenuate cocaine-induced toxicity and locomotor activity. Eur. J. Pharmacol. 1999, 370:225-232.
43. Narita N., Hashimoto K., Tomitaka S., Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur. J. Pharmacol. 1996, 307:117-119.
44. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
45. Nestler E.J., Gould E., Manji H., Buncan M., Duman R.S., Greshenfeld H.K., Hen R., Koester S., Lederhendler I., Meaney M., Robbins T., Winsky L., Zalcman S. Preclinical models: status of basic research in depression. Biol. Psychiatry 2002, 52:503-528.
46. Nishimura T., Ishima T., Iyo M., Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One 2008, 3:e2558.
47. Pande A., Geneve J., Scherrer B., Smith F., Leadbetter R., de Meynard C. A placebo-controlled trial of igmesine in the treatment of major depression. Eur. Neuropsychopharmacol. 1999, 9:138.
48. Paul R., Schaaff N., Padberg F., Moller H.J., Frodl T. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J. Biol. Psychiatry 2009, 10:241-244.
49. Pharmaprojects Igmesine hydrochloride, accession number 15962 2004, PJB Publications, Ltd.
50. Popik P., Kos T., Sowa-Kucma M., Nowak G. Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology (Berl) 2008, 198:421-430.
51. Price R.B., Nock M.K., Charney D.S., Mathew S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol. Psychiatry 2009, 66:522-526.
52. Schmidt A., Lebet L., Koe B.K., Seeger T., Heym J. Sertraline potently displaces (+)-[3H]3-PPP binding to sigma site in rat brain. Eur. J. Pharmacol. 1989, 165:335-336.
53. Seeman P., Guan H.C., Hirbec H. Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse 2009, 63:698-704.
54. Skuza G. Potential antidepressant activity of sigma ligands. Pol. J. Pharmacol. 2003, 55:923-934.
55. Skuza G., Rogoz Z. A potential antidepressant activity of SA4503, a selective sigma 1 receptor agonist. Behav. Pharmacol. 2002, 13:537-543.
56. Skuza G., Rogoz Z. Sigma1 receptor antagonists attenuate antidepressant-like effect induced by co-administration of 1,3 di-o-tolylguanidine (DTG) and memantine in the forced swimming test in rats. Pol. J. Pharmacol. 2003, 55:1149-1152.
57. Su T.P., Hayashi T., Maurice T., Buch S., Ruoho A.E. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol. Sci. 2010, 31:557-566.
58. Takebayashi M., Hayashi T., Su T.P. Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: implications for antidepressants. J. Pharmacol. Exp. Ther. 2002, 303:1227-1237.
59. Takebayashi M., Hayashi T., Su T.P. A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors. Pharmacopsychiatry 2004, 37(Suppl. 3):S208-S213.
60. Ukai M., Maeda H., Nanya Y., Kameyama T., Matsuno K. Beneficial effects of acute and repeated administrations of sigma receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol. Biochem. Behav. 1998, 61:247-252.
61. Villard V., Meunier J., Chevallier N., Maurice T. Pharmacological interaction with the sigma 1-receptor in the acute behavioral effects of antidepressants. J. Pharmacol. Sci. 2011, 115:279-292.
62. Vilner B.J., Bowen W.D. Sigma receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture. Eur. J. Pharmacol. 1993, 244:199-201.
63. Vilner B.J., Bowen W.D. Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J. Pharmacol. Exp. Ther. 2000, 292:900-911.
64. Vilner B.J., de Costa B.R., Bowen W.D. Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability. J. Neurosci. 1995, 15:117-134.
65. Volz H.P., Stoll K.D. Clinical trials with sigma ligands. Pharmacopsychiatry 2004, 37(Suppl. 3):S214-S220.
66. Wang J., Mack A.L., Coop A., Matsumoto R.R. Novel sigma (sigma) receptor agonists produce antidepressant-like effects in mice. Eur. Neuropsychopharmacol. 2007, 17:708-716.
67. Yan H.C., Cao X., Das M., Zhu X.H., Gao T.M. Behavioral animal models of depression. Neurosci. Bull. 2010, 26:327-337.
68. Yilmaz A., Schulz D., Aksoy A., Canbeyli R. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol. Biochem. Behav. 2002, 71:341-344.
69. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63:856-864.